769 Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors
Journal for immunotherapy of cancer, 2022, Vol.10 (Suppl 2), p.A800-A800 [Peer Reviewed Journal]2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;EISSN: 2051-1426 ;DOI: 10.1136/jitc-2022-SITC2022.0769
Full text available